Author

Y. Jin

Institutions: Sun Yat-sen University, Roche (Canada), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

Observed institutions: Sun Yat-sen University, Roche (Canada), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

OpenAlex ID: A5125194673

Prognostic nomogram for patients with HER2-negative metastatic gastric cancer receiving first-line PD-1 blockade

2026 · B. Fu, M. Zhang, et al. · ESMO Open · 1

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer

2026 · S.-A. Im, K. Kalinsky, et al. · ESMO Open

420RO Efficacy of inavolisib (INAVO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) with and without hyperglycaemia (HG) in the phase III INAVO120 trial

2026 · S. Loibl, K. Jhaveri, et al. · ESMO Open

Works count: 3

Citation count: 1

H-index: 1

I10-index: